The inhibitory effect of a selective alpha 2-adrenergic receptor antagonist on moderate- to severe-type asthma.

Abstract

Midaglizole (DG-5128), a novel selective alpha 2-adrenergic receptor antagonist, was administered to 17 patients with moderate to severe asthma in a single-dose, double-blind, randomized, crossover study. All patients also continued their regular treatment regimens. FEV1 increased significantly (p less than 0.05), and respiratory resistance decreased significantly (p less than 0.05). Wheezing and dry rales on auscultation improved in patients receiving 200 mg of midaglizole, and their assessment of overall benefit was also significantly better (p less than 0.05). Blood pressure and heart rate were unaffected. However, plasma glucose levels fell slightly. This study demonstrated the bronchodilating effect of midaglizole in moderate to severe bronchial asthma. This selective alpha 2-adrenergic antagonist may prove to be a useful addition to current treatment regimens for asthma.

• Authors: Y Yoshie, K Iizuka, T Nakazawa
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 84 Issue 5 Pt 1 Pg. 747-52 (Nov 1989) ISSN: 0091-6749 [Print] United States
• PMID: 2572618 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Antagonists
• Imidazoles
• midaglizole

Topics

• Adrenergic alpha-Antagonists (adverse effects, therapeutic use)
• Adult
• Aged
• Asthma (drug therapy, physiopathology)
• Double-Blind Method
• Female
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Male
• Middle Aged
• Randomized Controlled Trials as Topic
• Respiratory Mechanics (drug effects)